Lianhua Qingwen for COVID-19

Home

Lianhua Qingwen has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.

Lianhua Qingwen Submit Updates

Xia et al., Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID‐19, Cell Proliferation, doi:10.1111/cpr.12949

Xu et al., Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study, Phytomedicine, doi:10.1016/j.phymed.2023.154665

Mardaneh et al., Inhibiting NF-κB During Cytokine Storm in COVID-19: Potential Role of Natural Products as a Promising Therapeutic Approach, MDPI AG, doi:10.20944/preprints202106.0130.v1

Yao et al., Therapeutic drug combinations against COVID-19 obtained by employing a collaborative filtering method, Heliyon, doi:10.1016/j.heliyon.2023.e14023

Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit